Gratus Capital LLC boosted its position in Novartis AG (NYSE:NVS) by 12.3% in the 4th quarter, HoldingsChannel reports. The firm owned 111,836 shares of the company’s stock after buying an additional 12,267 shares during the period. Novartis accounts for about 1.2% of Gratus Capital LLC’s holdings, making the stock its 16th largest holding. Gratus Capital LLC’s holdings in Novartis were worth $9,390,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. WFG Advisors LP increased its stake in Novartis by 38.1% in the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock valued at $102,000 after purchasing an additional 337 shares in the last quarter. Wealthcare Advisory Partners LLC purchased a new position in Novartis during the third quarter worth $106,000. Cable Hill Partners LLC increased its position in Novartis by 588.8% during the third quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock worth $112,000 after buying an additional 1,107 shares in the last quarter. Calton & Associates Inc. purchased a new position in Novartis during the fourth quarter worth $118,000. Finally, SeaCrest Wealth Management LLC purchased a new position in Novartis during the fourth quarter worth $124,000. 11.09% of the stock is owned by hedge funds and other institutional investors.
Several research firms have weighed in on NVS. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a research report on Tuesday, October 24th. Nord/LB reissued a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. Bank of America downgraded Novartis from a “neutral” rating to an “underperform” rating in a research report on Wednesday, December 6th. Leerink Swann raised their price target on Novartis from $89.00 to $91.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Finally, UBS Group reissued a “neutral” rating on shares of Novartis in a research report on Monday, January 15th. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company. Novartis has a consensus rating of “Hold” and an average price target of $85.32.
Novartis (NYSE:NVS) last announced its quarterly earnings data on Wednesday, January 24th. The company reported $1.20 EPS for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.04. The business had revenue of $12.92 billion during the quarter, compared to the consensus estimate of $12.65 billion. Novartis had a return on equity of 16.03% and a net margin of 15.69%. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.14 earnings per share. analysts expect that Novartis AG will post 5.36 EPS for the current year.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.